Heart Failure with Preserved Ejection Fraction
- PMID: 29414252
- DOI: 10.1146/annurev-med-041316-090654
Heart Failure with Preserved Ejection Fraction
Abstract
Heart failure (HF) is a clinical syndrome of diverse etiologies and can be associated with preserved, reduced, or mid-range ejection fraction (EF). In the community, heart failure with preserved ejection fraction (HFpEF) is emerging as the most common form of HF. There remains considerable uncertainty regarding its pathogenesis, diagnosis, and optimal therapeutic approach. Hypotheses have been advanced to explain the underlying pathophysiology responsible for HFpEF, but to date, no specific therapy based on these hypotheses has been proven to improve outcomes in HFpEF. We provide a clinically focused review of the epidemiology, clinical presentation, diagnostic approach, pathophysiology, and treatment of HFpEF.
Keywords: cardiomyopathy; diastolic heart failure; hypertension; pulmonary hypertension.
Similar articles
-
Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.Int J Cardiol. 2017 Apr 1;232:86-92. doi: 10.1016/j.ijcard.2017.01.048. Epub 2017 Jan 5. Int J Cardiol. 2017. PMID: 28100428
-
Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.Am J Med. 2020 Oct;133(10):1187-1194. doi: 10.1016/j.amjmed.2020.02.040. Epub 2020 Apr 6. Am J Med. 2020. PMID: 32272101 Free PMC article.
-
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.Curr Opin Cardiol. 2015 May;30(3):250-8. doi: 10.1097/HCO.0000000000000163. Curr Opin Cardiol. 2015. PMID: 25807227 Free PMC article. Review.
-
Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.Heart Fail Rev. 2015 Nov;20(6):643-53. doi: 10.1007/s10741-015-9506-7. Heart Fail Rev. 2015. PMID: 26404098 Review.
-
In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.Int J Cardiol. 2014 May 1;173(2):163-9. doi: 10.1016/j.ijcard.2014.02.018. Epub 2014 Feb 22. Int J Cardiol. 2014. PMID: 24630337
Cited by
-
Effects of treatment of non-alcoholic fatty liver disease on heart failure with preserved ejection fraction.Front Cardiovasc Med. 2023 Jan 12;9:1120085. doi: 10.3389/fcvm.2022.1120085. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36712249 Free PMC article. Review.
-
Porcupine inhibitor CGX1321 alleviates heart failure with preserved ejection fraction in mice by blocking WNT signaling.Acta Pharmacol Sin. 2023 Jun;44(6):1149-1160. doi: 10.1038/s41401-022-01025-y. Epub 2022 Dec 6. Acta Pharmacol Sin. 2023. PMID: 36473990 Free PMC article.
-
SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes.Circ Res. 2022 Nov 11;131(11):926-943. doi: 10.1161/CIRCRESAHA.121.318988. Epub 2022 Oct 24. Circ Res. 2022. PMID: 36278398 Free PMC article.
-
Heart failure with preserved ejection fraction and non-alcoholic fatty liver disease: new insights from bioinformatics.ESC Heart Fail. 2023 Feb;10(1):416-431. doi: 10.1002/ehf2.14211. Epub 2022 Oct 20. ESC Heart Fail. 2023. PMID: 36266995 Free PMC article.
-
Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study.ESC Heart Fail. 2023 Feb;10(1):322-333. doi: 10.1002/ehf2.14068. Epub 2022 Oct 11. ESC Heart Fail. 2023. PMID: 36221795 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
